Gerresheimer's €1.5bn Divestment Exposes a Valuation Paradox That Even Goldman's Stake Can't Resolve
Published on 08/07/2026 at 18:22 | Redaktion boerse-global.de
The arithmetic is stark enough to give any investor pause. Gerresheimer's entire market capitalisation stands at roughly €917 million — a figure that falls short of the €1.5 billion the Düsseldorf-based pharmaceutical packaging specialist is set to receive from the sale of its US subsidiary Centor US Holding and its global plastic primary packaging business to Apax Partners funds. In other words, the market is pricing the whole company below the value of what it has just agreed to shed.
That disconnect helps explain why the stock has become a battleground for institutional investors with sharply divergent views. Goldman Sachs has been steadily building its position, disclosing on 29 July that it crossed the 19.83 percent threshold in Gerresheimer's share capital — 9.99 percent held directly and 9.83 percent via financial instruments. The move follows an earlier notification in early August revealing a 19.67 percent stake as of 24 July. The timing is notable: the bank's accumulation has run parallel to the divestment negotiations, suggesting the prospect of meaningful deleveraging is a key draw.
Rating agencies split on the deal's significance
The Apax transaction, announced on Thursday, is being read very differently across the sell-side. UBS responded on Wednesday by lifting its rating from "Sell" to "Neutral", with analyst Olivier Calvet more than doubling the price target from €12.90 to €28.50, citing the debt reduction enabled by the disposals. Barclays, by contrast, struck a more cautious tone at the end of July, keeping its "Sell" recommendation while raising its target from €17.00 to €25.00. The divergence underscores a broader market ambivalence: the deal is acknowledged as progress, yet doubts persist about the group's operational health.
Those doubts are rooted in a troubled recent history. Gerresheimer finally published its audited 2025 annual results at the end of June, months behind schedule, after internal investigations into accounting irregularities stalled the process. The year closed with a group loss of €318.7 million, weighed down by €521.5 million in writedowns on Sensile Medical and the Moulded Glass Chicago plant. The investigations, triggered in February, uncovered violations of internal guidelines and IFRS rules in revenue recognition during 2024 and 2025, prompting the engagement of a second auditing firm.
Should investors sell immediately? Or is it worth buying Gerresheimer?
A tightening financial calendar
The accounting problems have forced a delicate balancing act with creditors. In April, Gerresheimer negotiated an extension with holders of a €870 million Schuldschein loan until the end of September, buying time to complete the audited financials. That deadline now coincides with a broader refinancing effort: with Lazard advising, the company aims to finalise a comprehensive debt refinancing by September, and its annual general meeting is scheduled for 1 September.
Guidance for the current fiscal year reflects the strain. Revenue is expected to land in the lower half of the €2.3 billion to €2.4 billion range, with adjusted EBITDA margin between 17 and 18 percent. Free cash flow is projected at minus €50 million to minus €100 million — a negative figure that underscores the urgency of the refinancing work.
Market scepticism persists despite operational progress
The share price tells its own story of investor wariness. At €26.16, the stock is down 1.51 percent on the day and remains 44.03 percent below its 52-week high of €46.74 reached in August last year. Over the past 12 months, the shares have lost 41 percent, a slide that reflects not only Gerresheimer's internal troubles but also the cooling of the GLP-1 boom that once cast the company as a prime beneficiary. With disappointing clinical data and cautious forecasts from major pharmaceutical groups weighing on the sector, the tailwind has faded noticeably.
There are, to be fair, some signs of technical stabilisation. The stock trades roughly 8 percent above its 200-day average, and a degree of bottoming has emerged since February's yearly low. Yet the 30-day trend remains negative, with a further 9 percent decline, and volatility sits at nearly 46 percent — hardly the profile of a stock finding its footing.
Gerresheimer at a turning point? This analysis reveals what investors need to know now.
Operationally, Gerresheimer continues to make incremental advances. A new pharmaceutical packaging plant in Zhenjiang Dagang, China, came on line in July, and the Pfreimd site commissioned a photovoltaic system for its own power supply around the same time. These steps, however, are unlikely to shift sentiment on their own.
The question hanging over the stock is whether the Apax proceeds represent a genuine turning point or merely a financial patch. Goldman's growing stake signals institutional conviction in the restructuring narrative, but with the refinancing deadline approaching and the market valuing the company below its own divestment proceeds, the burden of proof rests squarely on management.
Ad
Gerresheimer Stock: New Analysis - 7 August
Fresh Gerresheimer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
